Allergan to launch eyelash enhancer

Share this article:

Allergan is gearing up for the launch of Latisse, the first FDA-approved cosmetic eyelash enhancer, with a website and consumer ads in development.

Allergan estimates that global sales of Latisse could exceed $500 million annually. A complete product website, at www.latisse.com, goes live on January 15. Approved in December, the product will land on drugstore shelves in “late January, early February,” according to Heather Katt, an Allergan spokesperson. Consumer ads will launch “when appropriate,” following the availability of the drug, said Katt. Chandler Chicco and Grey, both of New York City, are handling public relations and advertising for Latisse, respectively. California-based Pacific Communications is Allergan's AOR for professional and patient communications in support of Latisse.

Scott Whitcup, Allergan's EVP of research and development, said in a statement that Latisse fulfills an unmet need in the medical aesthetic marketplace by increasing the growth of eyelashes, making them longer, thicker and darker. 

Bimatoprost ophthalmic solution is also marketed as Lumigan, Allergan's glaucoma eye drops. FDA approved Lumigan in 2001, and Allergan discovered its eyelash-enhancing properties through patient reports.

Latisse is available by prescription only, and is recommended as a once-daily treatment. A 30-day supply will cost $120, the Wall Street Journal reported. A 30-day supply of Lumigan, without insurance, costs $185.99 at Walgreens.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.